Lakvinimod

Lakvinimod
Nazivi
	IUPAC nazivs 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-; N-phenyl-1,2-dihydroquinoline-3-carboxamide
Identifikacija
CAS broj	248282-07-7;
3D model (Jmol)	interaktivna slika;
ECHA InfoCard	100.220.145
PubChem C ID	216469;
	SMILES CCN(c1ccccc1)C(=O)C\3=C(/O)c2c(Cl)cccc2N(C)C/3=O; ; ; ; ; ;
Svojstva
Hemijska formula	C19H17ClN2O3
Molarna masa	356,803 g/mol
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	Reference infokutije

Lakvinimod (Laquinimod) je eksperimentalni imunomodulator koji su razvile kompanije Active Biotech i Teva. On se trenutno istražuje kao oralni tretman za multiplu sklerozu (MS).

Laquinimod je zamena za neuspešni eksperimentalni imunomodulator linomide kompanije Active Biotech.^[3]

Klinička ispitivanja[уреди | уреди извор]

Ovo jedinjenje je bilo studirano u dva klinička ispitivanja faze II koristeći sukcesivne magnetno rezonantne snimke (MRI). Laquinimod izgleda da može da umanji aktivnost MS bolesti.^[4]^[5] Međutim, respons na datu dozu je bio protivrečan između nalaza ove dve studije.^[6]

Ispitivanje faze III je počelo 2008 godine.

Vidi još[уреди | уреди извор]

Multipla skleroza

Literatura[уреди | уреди извор]

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Tan IL; Lycklama à Nijeholt GJ; Polman CH; et al. (2000). „Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials”. Mult Scler. 6 (2): 99—104. PMID 10773855.
^ Comi G; Pulizzi A; Rovaris M; et al. (2008). „Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study”. Lancet. 371 (9630): 2085—92. PMID 18572078. doi:10.1016/S0140-6736(08)60918-6.
^ Polman C; Barkhof F; Sandberg-Wollheim M; et al. (2005). „Treatment with laquinimod reduces development of active MRI lesions in relapsing MS”. Neurology. 64 (6): 987—91. PMID 15781813. doi:10.1212/01.WNL.0000154520.48391.69.
^ Keegan BM, Weinshenker BG (2008). „Laquinimod, a new oral drug for multiple sclerosis”. Lancet. 371 (9630): 2059—60. PMID 18572062. doi:10.1016/S0140-6736(08)60894-6.

Spoljašnje veze[уреди | уреди извор]

Podaci u NIH registru studija

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[2] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[3] Tan IL; Lycklama à Nijeholt GJ; Polman CH; et al. (2000). „Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials”. Mult Scler. 6 (2): 99—104. PMID 10773855.

[pmid18572078-4] Comi G; Pulizzi A; Rovaris M; et al. (2008). „Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study”. Lancet. 371 (9630): 2085—92. PMID 18572078. doi:10.1016/S0140-6736(08)60918-6.

[pmid15781813-5] Polman C; Barkhof F; Sandberg-Wollheim M; et al. (2005). „Treatment with laquinimod reduces development of active MRI lesions in relapsing MS”. Neurology. 64 (6): 987—91. PMID 15781813. doi:10.1212/01.WNL.0000154520.48391.69.

[6] Keegan BM, Weinshenker BG (2008). „Laquinimod, a new oral drug for multiple sclerosis”. Lancet. 371 (9630): 2059—60. PMID 18572062. doi:10.1016/S0140-6736(08)60894-6.

[1]

[2]

[3]

[4]

[5]

[6]